research Sexual Medicine Reviews—The Premiere Review Journal for the Field of Sexual Medicine
Current treatments for recurrent ischemic priapism are not well-defined and need more research.
Search
for
Sort by
Research
30-60 / 1000+ results
research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Trimodal Mini‐Invasive Therapy for Stable‐Phase Peyronie's Disease: A Two‐Center Real‐Life Prospective Pilot Study
PRP injections are safe but don't significantly improve Peyronie's Disease.
research The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.
research Recent Advances in the Medical and Surgical Treatment of Priapism
New treatments for long-lasting erections improve outcomes but must be timely to avoid lasting damage.
research 124 The Persistent Effects of 5α-reductase Inhibitors Used in the Treatment of Androgenic Alopecia on Men’s Health
Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
research 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research The Effect of 5 -Reductase Inhibitors on Erectile Function
5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
research 1194: The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study
Doxazosin and finasteride negatively affect sexual function in men with BPH.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects
Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.
research Repurposing existing drugs for COVID-19: an endocrinology perspective
Existing drug dexamethasone may lower death risk in severe COVID-19 cases; more research needed for other drugs.
research Gender Differences in Cardiac Hypertrophy
Women generally handle heart enlargement better than men, but it's riskier for them if it occurs; hormones like estrogen offer some protection.
research The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride
Lovastatin doesn't improve lower urinary tract symptoms treatment.
research The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption
Finasteride can cause lasting sexual dysfunction, depression, and other side effects, needing more research for treatment.
research The use of phosphodiesterase inhibitors for the treatment of alopecia
Caffeine shows promise for treating some types of hair loss, but more research is needed.
research Erectile Dysfunction in Young Adults: A Narrative Review
Erectile dysfunction in young men is caused by both mental and physical factors and needs a personalized treatment approach.
research Health consequences of anabolic steroids: a sexual-medicine perspective
Anabolic steroid abuse can cause sexual, fertility, and health problems.
research Medical management of benign prostatic hyperplasia
Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.
research 5α-reductase inhibitors/finasteride
Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Оптимизация подходов консервативной терапии доброкачественной гиперплазии предстательной железы ингибиторами 5-альфаредуктазы. Клинико-морфологическое исследование
5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
research HP-01-004 Histomorphometrical Evaluation of The Corpus Cavernosum of Hypertensive Rats Treated with 5-Alpha-Reductase Inhibitors
5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
research Finasteride and the 5-Alpha Reductase Inhibitors
research 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.